Compare Novartis AG (NVS) vs Peloton Interactive Inc (PTON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Peloton Interactive Inc — how do they compare? Novartis AG trades at $153.53 (market cap $298.18B), while Peloton Interactive Inc trades at $5.6 (market cap $2.42B). The key difference: Novartis AG is far larger — about 123.2× Peloton Interactive Inc's market cap, and Novartis AG pays a 3.02% dividend while Peloton Interactive Inc pays none. Which is the better fit depends on your goals.
| NVS | PTON | |
|---|---|---|
Market Cap | $298.18B | $2.42B |
Sector | Health | Consumer Cyclical |
52-Week High | $168.62 | $9.00 |
52-Week Low | $119.31 | $3.71 |
Enterprise Value | $339.50B | $2.92B |
Dividend Yield | 3.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Peloton Interactive (PTON) trades at $5.68, up 3.18% with a bearish technical signal despite recent earnings beat. The company achieved its first annual net profit in fiscal 2026 with $63M net income, though revenue declined to $2.4B. Valuation metrics show a P/E of 40.54 and P/S of 1.01, while negative shareholder equity of -$413.7M reflects historical losses. Recent news highlights profitability progress but concerns about subscriber declines and conservative 2027 guidance.
PTON presents a turnaround story with improving profitability but faces significant revenue headwinds. The stock offers potential upside if subscriber stabilization occurs, though high debt levels and competitive pressures pose substantial risks. Analyst consensus is divided with 50% buy ratings, suggesting cautious optimism amid ongoing business transformation challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Peloton Interactive Inc
Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product revenue consists of sales of bike and tread and related accessories, associated fees for delivery and installation, and extended warranty agreements. Subscription revenue consists of revenue generated from monthly Connected Fitness Subscription and Digital Subscription. The company generates the majority of the revenue from the sale of Connected Fitness Products.
Read more on PTON →
